Biomonitoring

Adverse Effects of Engineered Nanomaterials

Volumn , Issue , 2012, Pages 45-62

  Bergamaschi, Enrico ^a   Magrini, Andrea ^b  

^a UNIVERSITY OF PARMA MEDICAL SCHOOL   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84867579392     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-386940-1.00003-9     Document Type: Chapter

References (109)

1. Zielhuis R.L., Henderson P.T. Definitions of monitoring activities and their relevance for the practice of occupational health. Int Arch Occup Environ Health 1986, 57:249-257.
2. Schulte P.A., Hauser J.E. The use of biomarkers in occupational health research, practice, and policy. Toxicol Lett 2011, (doi:10.1016/j.toxlet.2011.03.027).
3. Mutti A. Biomarkers of exposure and effect for non carcinogenic end-points. International programme on chemical safety. Environmental Health Criteria 222, Biomarkers in risk assessment: validity and validation, 104 2001, World Health Organization, Geneva, pp. 130-136.
4. Lauwerys R.R., Hoet P. Industrial chemical exposure. Guidelines for biological monitoring 1993, Lewis Publishers, Boca Raton, vol. 1. 2nd ed.
5. NRC, National Research Council Biological markers in environmental health research. Environ Health Perspect 1987, 74:3-9.
6. Watson W.P., Mutti A. Role of biomarkers in monitoring exposure to chemicals: Present position, future prospects. Biomarkers 2004, 9:211-242.
7. Smolders R., Bartonova A., Boogaard P.J., et al. The use of biomarkers for risk assessment: Reporting from the INTARESE/ENVIRISK Workshop in Prague. Int J Hyg Environ Health 2010, 213:395-400.
8. Angerer J., Ewers U., Wilhelm M. Human biomonitoring: State of the art. Int J Hyg Environ Health 2007, 210:201-228.
9. Manno M., Viau C., Cocker J., et al. Biomonitoring for occupational health risk assessment (BOHRA). Toxicol Lett 2010, 192:3-16.
10. Li N., Nel A. Feasibility of biomarker studies for engineered nanoparticles. What can be learned from air pollution research. J Occup Environ Med 2011, 53:S74-S79.
11. Riviere J.E., Tran C.L. Pharmacokinetics of nanomaterials. Nanotoxicology. Characterization, dosing and health effects 2007, 127-140. Informa Healthcare, New York.
12. Aschberger K., Johnston H.J., Stone V., et al. Review of carbon nanotubes toxicity and exposure. Appraisal of human health risk assessment based on open literature. Crit Rev Toxicol 2010, 40:759-790.
13. Wittmaack K. In search of the most relevant parameter for quantifying lung inflammatory response to nanoparticle exposure: Particle number, surface area, or what?. Environ Health Perspect 2007, 115:187-194.
14. Oberdörster G., Sharp Z., Atudorei V., et al. Translocation of inhaled ultrafine particles to the brain. Inhal Toxicol 2004, 16:437-445.
15. Schmid O., Möller W., Semmler-Behnke M., et al. Dosimetry and toxicology of inhaled ultrafine particles. Biomarkers Suppl 2009, 1:67-73.
16. Tran C.L., Buchanan D., Cullen R.T., Searl A., Jones A.D., Donaldson K. Inhalation of poorly soluble particles. II. Influence of particle surface area on inflammation and clearance. Inhal Toxicol 2000, 12:1113-1126.
17. Kuempel E.D., Tran C.L., Castranova V., Bailer A.J. Lung dosimetry and risk assessment of nanoparticles: Evaluating and extending current models in rats and humans. Inhal Toxicol 2006, 18:717-724.
18. Kuempel E. Estimating nanoparticle dose in humans: Issues and challenges. Nanotoxicology. Characterization, dosing and health effects 2007, 141-152. Informa Healthcare, New York.
19. Chen H.H., Chien C.C., Petibois C., et al. Quantitative analysis of nanoparticle internalization in mammalian cells by high resolution X-ray microscopy. J Nanobiotechnol 2011, 9:14-29.
20. Helland A., Wick P., Koehler A., Schmid K., Som C. Reviewing the environmental and human health knowledge base of carbon nanotubes. Environ Health Perspect 2007, 115:1125-1131.
21. Pappi T., Schiffmann D., Weiss D., Castranova V., Vallyathan V., Rahman Q. Human health implications of nanomaterial exposure. Nanotoxicology 2008, 2:9-27.
22. Brain J.D., Curran M.A., Donaghey T., Molina R.A. Biologic responses to nanomaterials depend on exposure, clearance, and material characteristics. Nanotoxicology 2009, 3:174-180.
23. Muller J., Huaux F., Moreau N., et al. Respiratory toxicity of multi-wall carbon nanotubes. Toxicol Appl Pharmacol 2005, 207:221-231.
24. Muller J., Huaux F., Fonseca A., et al. Structural defects play a major role in the acute lung toxicity of multiwall carbon nanotubes: Toxicological aspects. Chem Res Toxicol 2008, 21:1698-1705.
25. Shvedova A.A., Kisin E., Murray A.R., et al. Inhalation vs. aspiration of singlewalled carbon nanotubes in C57BL/6 mice: Inflammation, fibrosis, oxidative stress, and mutagenesis. Am J Physiol Lung Cell Mol Physiol 2008, 295:L552-L565.
26. Choi H.S., Ashitate Y., Lee J.H., et al. Rapid translocation of nanoparticles from the lung airspaces to the body. Nat Biotechnol 2010, 28:1300-1303.
27. Gibson R.M. Understanding the potential neurotoxicology of nanoparticles. Nanotoxicology. Characterization, dosing and health effects 2007, 299-316. Informa Healthcare, New York.
28. Donaldson K., Newby D.E., MacNee W., Duffin R., Lucking A.J., Mills N.L. Pulmonary and cardiovascular effects of nanoparticles. Nanotoxicology. Characterization, dosing and health effects 2007, Informa Healthcare, New York, pp. 267-98.
29. Legramante J.M., Valentini F., Magrini A., et al. Cardiac autonomic regulation after lung exposure to carbon nanotubes. Hum Exper Toxicol 2009, 28:369-375.
30. Oberdörster G., Elder A., Rinderknecht A. Nanoparticles and the brain: cause for concern?. J Nanosci Nanotechnol 2009, 9:4996-5007.
31. Sharma H.S., Sharma A. Conference scene: Nanoneuroprotection and nanoneurotoxicity: Recent progress and future perspectives. Nanomedicine (Lond) 2010, 5:533-537.
32. Erdely A., Hulderman T., Salmen R., et al. Cross-talk between lung and systemic circulation during carbon nanotube respiratory exposure. Potential biomarkers. Nano Lett 2009, 9:36-43.
33. Lotti M., Olivato I., Bergamo L. Inflammation and short-term cardiopulmonary effects of particulate matter. Nanotoxicology 2009, 1-6. DOI: 10.1080/17435390802538763.
34. Shvedova A., Kagan V.E., Fadeel B. Close encounters of the small kind: Adverse effects of man-made materials interfacing with the nano-cosmos of biological systems. Annu Rev Pharmacol Toxicol 2010, 50:63-88.
35. Poma A., Di Giorgio M.L. Toxicogenomics to improve comprehension of the mechanisms underlying responses of in vitro and in vivo systems to nanomaterials: A review. Curr Genomics 2008, 9:571-585.
36. Yang B., Wang Q., Lei R., et al. Systems toxicology used in nanotoxicology: Mechanistic insights into the hepatotoxicity of nano-copper particles from toxicogenomics. J Nanosci Nanotechnol 2010, 10:8527-8537.
37. Chui D., Tian F., Ozkan C.S., Wang M.W., Gao H. Effect of single wall carbon nanotubes on human HEK293 cells. Toxicol Lett 2005, 155:73-85.
38. Higashisaka K., Yoshioka Y., Yamashita Y., et al. Acute phase proteins as biomarkers for predicting the exposure and toxicity of nanomaterials. Biomaterials 2011, 32:3-9.
39. Waters K.M., Masiello L.M., Zangar R.C., et al. Macrophage responses to silica nanoparticles are highly conserved across particle sizes. Toxicol Sci 2008, 104:155-162.
40. Teeguarden J.G., Webb-Robertson B.J., Waters K.M., et al. Comparative proteomics and pulmonary toxicity of instilled single-walled carbon nanotubes, crocidolite asbestos, and ultrafine carbon black in mice. Toxicol Sci 2011, 120:123-135.
41. Henderson R.F., Bechtold W.E., Bond J.A., Sun J.D. The use of biological markers in toxicology. Crit Rev Toxicol 1989, 20:65-82.
42. Frampton M.W., Utell M.J., Zareba W., et al. Effects of exposure to ultrafine carbon particles in healthy subjects and subjects with asthma. Res Rep Health Effect Inst 2004, 126:1-47.
43. Geiser M., Kreyling W. Deposition and biokinetics of inhaled nanoparticles. Part Fibre Toxicol 2010, 7:2-17.
44. Holgate S.T. Exposure, uptake distribution and toxicity of nanomaterials in humans. J Biomed Nanotechnol 2010, 6:1-19.
45. Schleh C., Rothen-Rutishauser B., Kreyling W.G. The influence of pulmonary surfactant on nanoparticulate drug delivery systems. Eur J Pharm Biopharm 2011, 77:350-352.
46. Borm P., Klaessig F.C., Landry T.D., et al. Research strategies for safety evaluation of nanomaterials, Part V: Role of dissolution in biological fate and effects of nanoscale particles. Toxicol Sci 2006, 90:23-32.
47. Colognato R., Bonelli A., Ponti J., et al. Comparative genotoxicity of cobalt nanoparticles and ions on human peripheral leukocytes in vitro. Mutagenesis 2008, 23:377-382.
48. Pettibone J.M., Adamcakova-Dodd A., Thorne P.S., O'Shaughnessy P.T., Weydert J.A., Grassian V.H. Inflammatory response of mice following inhalation exposure to iron and copper nanoparticles. Nanotoxicology 2008, 2:189-204.
49. Johnston H.J., Hutchison G., Christensen F.M., Peters S., Hankin S., Stone V. A review of the in vivo and in vitro toxicity of silver and gold particulates: Particle attributes and biological mechanisms responsible for the observed toxicity. Crit Rev Toxicol 2010, 40:328-346.
50. Broday D.M., Agnon Y. Asymmetric human lung morphology induce particle deposition variation. J Aerosol Sci 2007, 38:701-718.
51. Goldoni M., Caglieri A., De Palma G., et al. Development and set-up of a portable device to monitor airway exhalation and deposition of particulate matter. Biomarkers 2009, 14:326-339.
52. Goldoni M., Catalani S., De Palma G., et al. Exhaled breath condensate as a suitable matrix to assess lung dose and effects in workers exposed to cobalt and tungsten. Environ Health Perspect 2004, 112:1293-1298.
53. Goldoni M., Caglieri A., Poli D., et al. Determination of hexavalent chromium in exhaled breath condensate and environmental air among chrome plating workers. Anal Chim Acta 2006, 562:229-235.
54. Corradi M., Acampa O., Goldoni M., et al. Metallic elements in exhaled breath condensate of patients with interstitial lung diseases. J Breath Res 2009, 3. 046003.
55. Montuschi P. Analysis of exhaled breath condensate in respiratory medicine: Methodological aspects and potential clinical applications. Ther Adv Resp Dis 2007, 1:5-23.
56. Corradi M., Gergelova P., Mutti A. Use of exhaled breath condensate to investigate occupational lung diseases. Curr Opin Allergy Clin Immunol 2010, 10:93-98.
57. Gube M., Ebel J., Brand P., et al. Biological effect markers in exhaled breath condensate and biomonitoring in welders: Impact of smoking and protection equipment. Int Arch Occup Environ Health 2010, 83:803-811.
58. Horvath I., Lazar Z., Gyulai N., Kollai M., Losonczy G. Exhaled biomarkers in lung cancer. Eur Respir J 2009, 34:261-275.
59. Horvath I., Hunt J., Barnes P.J., et al. ATS/ERS Task Force on Exhaled Breath Condensate. Exhaled breath condensate: Methodological recommendations and unresolved questions. Eur Respir J 2005, 26:523-548.
60. Poli D., Carbognani P., Corradi M., et al. Exhaled volatile organic compounds in patients with non-small cell lung cancer: Cross sectional and nested short-term follow-up study. Respir Res 2005, 6:71.
61. Poli D., Goldoni M., Corradi M., et al. Determination of aldehydes in exhaled breath of patients with lung cancer by means of on fiber derivatisation SPME-GC/MS. J Chromatogr B Analyt Technol Biomed Life Sci 2010, 878:2643-2651.
62. Corradi M., Rubinstein I., Andreoli R., et al. Aldehydes in exhaled breath condensate of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003, 167:1380-1386.
63. Forman H.J. Reactive oxygen species and α,β-unsaturated aldehydes as second messengers in signal transduction. Ann NY Acad Sci 2010, 1203:35-44.
64. Pacher P., Beckman J.S., Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev 2007, 87:315-424.
65. Corradi M., Montuschi P., Donnelly L.E., Pesci A., Kharitonov S.A., Barnes P.J. Increased nitrosothiols in exhaled breath condensate in inflammatory airway diseases. Am J Respir Crit Care Med 2001, 163:854-858.
66. Laumbach R.J., Kipen H.M. Acute effects of motor vehicle traffic-related air pollution exposures on measures of oxidative stress in human airways. Ann NY Acad Sci 2010, 1203:107-112.
67. Delfino R.J., Staimer N., Tjoa T., et al. Air pollution exposures and circulating biomarkers of effect in a susceptible population: Clues to potential causal component mixtures and mechanisms. Environ Health Perspect 2009, 117:1232-1238.
68. Delfino R.J., Staimer N., Tjoa T., et al. Association of biomarkers of systemic inflammation with organic components and source tracers in quasi-ultrafine particles. Environ Health Perspect 2010, 118:756-762.
69. Radomski A., Jurasz P., Alonso-Escolano D., et al. Nanoparticle-induced platelet aggregation and vascular thrombosis. Br J Pharmacol 2005, 146:882-893.
70. Jun E.-A., Lim K.M., Kim K., et al. Silver nanoparticles enhance thrombus formation through increased platelet aggregation and procoagulant activity. Nanotoxicology 2011, 5:157-167.
71. Li Z., Hulderman T., Salmen R., et al. Cardiovascular effects of pulmonary exposure to single-wall carbon nanotubes. Environ Health Perspect 2007, 115:377-382.
72. Nurkiewicz T.R., Porter D.W., Hubbs A.F., et al. Nanoparticle inhalation augments particle-dependent systemic microvascular dysfunction. Part Fibre Toxicol 2008, 5:1-16.
73. Vesterdal L.K., Folkmann J.K., Jacobsen N.R., et al. Pulmonary exposure to carbon black nanoparticles and vascular effects. Part Fibre Toxicol 2010, 7:33-48.
74. Hermans C., Bernard A. Lung epithelium-specific proteins: Characteristics and potential applications as markers. Am J Respir Crit Care Med 1999, 159:646-678.
75. Broeckaert F., Arsalane K., Hermans C., et al. Lung epithelial damage at low concentrations of ambient ozone. Lancet 2000, 353:900-901.
76. Bergamaschi E., De Palma G., Mozzoni P., et al. Polymorphism of quinone-metabolizing enzymes and susceptibility to ozone-induced acute effects. Am J Respir Crit Care Med 2001, 163:1426-1431.
77. Alessandrini F., Weichenmeier I., van Miert E., et al. Effects of ultrafine particles-induced oxidative stress on Clara cells in allergic lung inflammation. Part Fibre Toxicol 2010, 7:11.
78. Liou S.H., Lin M.H., Hsu C.H., et al. Pilot study of health hazards among engineered nanoparticles manufacturing workers. Occup Environ Med 2010, 60(Suppl. 1). (A100).
79. Mills N.L., Donaldson K., Hadoke P.W., et al. Adverse cardiovascular effects of air pollution. Nat Clin Pract Cardiovasc Med 2009, 6:36-44.
80. Møller P., Jacobsen N.R., Folkmann J.K., et al. Role of oxidative damage in toxicity of particulates. Free Radic Res 2010, 44:1-46.
81. Loft S., Danielsen P.O., Mikkelsen L., Risom L., Forchhammer L., Møller P. Biomarkers of oxidative damage to DNA and repair. Biochem Soc Trans 2008, 36:1071-1076.
82. Møller P., Loft S. Oxidative damage to DNA and lipids as biomarkers of exposure to air pollution. Environ Health Perspect 2010, 118:1126-1136.
83. Cooke M.S., Henderson P.T., Evans M.D. Sources of extracellular, oxidatively modified DNA lesions: Implications for their measurement in urine. J Clin Biochem Nutr 2009, 45:255-270.
84. Sauvain J.J., Setyan A., Wild P., et al. Biomarkers of oxidative stress and its association with the urinary reducing capacity in bus maintenance workers. J Occup Med Toxicol 2011, 6:18.
85. Gonzalez L., Lison D., Kirsch-Volders M. Genotoxicity of engineered nanomaterials: A critical review. Nanotoxicology 2008, 2:252-273.
86. Singh N., Manshian B., Jenkins G.J.S., et al. NanoGenotoxicology: The DNA damaging potential of engineered nanomaterials. Biomaterials 2009, 30:3891-3914.
87. Ponti J., Sabbioni E., Munaro B., et al. Genotoxicity and morphological transformation induced by cobalt nanoparticles and cobalt chloride: An in vitro study in Balb/3T3 mouse fibroblasts. Mutagenesis 2009, 24:439-445.
88. 2. Hum Exp Toxicol 2009, 28:339-352.
89. Muller J., Decordier I., Hoet P.H., et al. Clastogenic and aneugenic effects of multi-wall carbon nanotubes in epithelial cells. Carcinogenesis 2008, 29:427-433.
90. Migliore L., Saracino D., Bonelli A., et al. Carbon nanotubes induce oxidative DNA damage in RAW 264.7 cells. Environ Mol Mutagen 2010, 51:294-302.
91. Karlsson H.L. The comet assay in nanotoxicology research. Anal Bioanal Chem 2010, 398:651-666.
92. Hu Y.L., Gao J.Q. Potential neurotoxicity of nanoparticles. Int J Pharm 2010, 394:115-121.
93. Wang Z., Zhao J., Li F., Gao D., Xing B. Adsorption and inhibition of acetylcholinesterase by different nanoparticles. Chemosphere 2009, 77:67-73.
94. Wang J., Rahman M.F., Duhart H.M., et al. Expression changes of dopaminergic system related genes in PC12 cells induced by manganese, silver, or copper nanoparticles. Neurotoxicology 2009, 30:926-933.
95. Wu J., Wang C., Sun J., Xue Y. Neurotoxicity of silica nanoparticles: Brain localization and dopaminergic neurons damage pathways. ACS Nano 2011, 5:4476-4489.
96. Manzo L., Artigas F., Martinez E., et al. Biochemical markers of neurotoxicity. A review of mechanistic studies and applications. Hum Exp Toxicol 1996, S1:20-35.
97. Smargiassi A., Mergler D., Bergamaschi E., Vettori M.V., Lucchini R., Apostoli P. Peripheral markers of catecholamine metabolism among workers occupationally exposed to manganese (Mn). Toxicol Lett 1995, 77:329-333.
98. Mutti A., Bergamaschi E., Alinovi R., Lucchini R., Vettori M.V., Franchini I. Serum prolactin in subjects occupationally exposed to manganese. Ann Clin Lab Sci 1996, 26:10-17.
99. Linse S., Cabaleiro-Lago C., Xue W.F., et al. Nucleation of protein fibrillation by nanoparticles. Proc Natl Acad Sci USA 2007, 104:8691-8696.
100. Simká M., Mattsson M.O. Risks from accidental exposures to engineered nanoparticles and neurological health effects: A critical review. Part Fibre Toxicol 2010, 7:42-57.
101. Nasterlack M., Zober A., Oberlinner C. Considerations on occupational medical surveillance in employees handling nanoparticles. Int Arch Occup Environ Health 2008, 81:721-726.
102. Hildebrandt K., Rücker R., Koenig W., et al. Short-term effects of air pollution: A panel study of blood markers in patients with chronic pulmonary disease. Part Fibre Toxicol 2009, 6:25-40.
103. Schulte P.A., Trout D., Zumwalde R.D., et al. Options for occupational health surveillance of workers potentially exposed to engineered nanoparticles: State of the science. J Occup Environ Med 2008, 50:517-526.
104. Schulte P.A., Schubauer-Berigan M.K., Mayweather C., Geraci C.L., Zumwalde R., McKernan J.L. Issues in the development of epidemiologic studies of workers exposed to engineered nanoparticles. J Occup Environ Med 2009, 51:323-335.
105. Bergamaschi E. Occupational exposure to nanomaterials: Present knowledge and future development. Nanotoxicology 2009, 3:194-201.
106. Albertini R.J. Developing sustainable studies on environmental health. Mutat Res 2001, 480-1:317-331.
107. Roux A., Lison D., Junot C., Heilier J.F. Applications of liquid chromatography coupled to mass spectrometry-based metabolomics in clinical chemistry and toxicology: A review. Clin Biochem 2011, 44:119-135.
108. Iavicoli I., Calabrese E.J., Nascarella M.A. Exposure to nanoparticles and hormesis. Dose-Response 2010, 8:501-517.
109. Seaton A., Tran L., Aitken R., Donaldson K. Nanoparticles, human health hazard and regulation. J R Soc Interface 2010, 7:S119-S129.